Our COVID-19 Response Efforts

Learn More

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

Learn More

Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review

Learn More

Johnson & Johnson Statement on COVID-19 Vaccine

ohnson & Johnson has been actively engaged in fighting pandemics for over a century. We have done it before, and we will do it again.

With our global reach comes a responsibility and unique ability to leverage our deep scientific expertise and extensive partnerships to take on this challenge. Our more than 130,000 employees around the world mobilized with urgency to address the critical needs of families, communities and healthcare providers around the world.

Our commitment to families around the world doesn’t change in a time of crisis: we’ll never stop taking care of you.

Please note that by clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.

Find the status of Johnson & Johnson’s COVID-19 vaccine in countries around the world.

Learn More

Johnson & Johnson’s COVID-19 Vaccine

March 31, 2020

Vaccines are critical to tackling the COVID-19 pandemic. Learn more about the science behind our vaccine and our commitment to safety and transparency.

Learn More
Supporting Frontline Healthcare Workers and Our Communities

April 01, 2020

Expanding the support we provide to our communities and the healthcare workers on the frontlines of responding to this crisis

Learn more
Caring for Employees During COVID-19

May 01, 2020

Supporting the safety, health and well-being of our employees.

Learn More
Resources for COVID-19 Education and Training

February 04, 2021

Access The Road to a Vaccine, our series hosted by Lisa Ling, vaccine education resources from our partners and training available for healthcare providers.

Learn More

COVID-19 Media Hub

Latest announcements on Johnson & Johnson’s efforts to address the pandemic and media resources.

Learn More

COVID-19 Timeline

Since the early days of the outbreak, Johnson & Johnson has been working with industry partners, governments and health authorities to help end the fast-moving COVID-19 pandemic through the development of a possible preventive vaccine candidate against SARS-CoV-2.

February 27, 2021

U.S. FDA authorizes single-dose Janssen COVID-19 vaccine for emergency use

February 19, 2021

Emergency Use Listing submitted to the World Health Organization

February 16, 2021

European Conditional Marketing Authorization Application submitted to the EMA

February 4, 2021

Application submitted to the U.S. FDA for Emergency Use Authorization

November 15, 2020

Initiation of ENSEMBLE 2 clinical trial

September 21, 2020

Initiation of Phase 3 ENSEMBLE clinical trial

July 30, 2020

Preclinical data published in Nature shows J&J’s investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection.

July 22, 2020

First-in-human Phase 1/2a clinical trial commenced.

June 10, 2020

J&J announces acceleration of its COVID-19 vaccine candidate: Phase 1/2a clinical trial to begin in second half of July.

April 23, 2020

J&J enters into a collaboration with Emergent BioSolutions, Inc., to support the manufacturing of its lead investigational COVID-19 vaccine candidate.

March 30, 2020

J&J announces a lead vaccine candidate will move into trials and pledges to supply 1B vaccines worldwide for emergency pandemic use. BARDA and J&J commit $1B to vaccine R&D.

March 27, 2020

J&J and the Johnson & Johnson Foundation announce a $50 million commitment to support frontline health workers battling COVID-19.

March 11, 2020

WHO declares the COVID-19 outbreak a pandemic.

February 26, 2020

The first case of COVID-19 was reported in South America, marking the spread of the disease to six of seven continents.

February 23, 2020

Europe has its first major outbreak of COVID-19, in the Lombardy region of northern Italy

February 18, 2020

J&J announces expanded collaboration with U.S. Department of Health & Human Services to accelerate discovery of potential COVID-19 treatments.

February 11, 2020

J&J announces collaboration with U.S. Department of Health & Human Services to accelerate development of a potential COVID-19 vaccine.

February 11, 2020

COVID-19 is announced as the official name of the disease caused by novel coronavirus. The virus is named SARS-CoV-2.

February 1, 2020

First death linked to 2019-nCoV was reported outside of China, in the Philippines.

January 30, 2020

WHO declares the 2019-nCoV outbreak a public health emergency of international concern (PHEIC).

January 12, 2020

J&J initiates efforts to develop a vaccine candidate against 2019-nCoV and to broadly collaborate with others to screen a library of antiviral molecules.

January 11, 2020

First death linked to 2019-nCoV.

January 7, 2020

WHO announces they have identified a new virus named 2019-nCoV, also known as Wuhan coronavirus. It is from the CoV family, which includes SARS and the common cold.

December 31, 2019

China alerted the World Health Organization (WHO) to several cases of pneumonia in Wuhan. The virus is unknown.